In vitro and in vivo anti‐epileptic efficacy of eslicarbazepine acetate in a mouse model of KCNQ2‐related self‐limited epilepsy. (9th November 2021)
- Record Type:
- Journal Article
- Title:
- In vitro and in vivo anti‐epileptic efficacy of eslicarbazepine acetate in a mouse model of KCNQ2‐related self‐limited epilepsy. (9th November 2021)
- Main Title:
- In vitro and in vivo anti‐epileptic efficacy of eslicarbazepine acetate in a mouse model of KCNQ2‐related self‐limited epilepsy
- Authors:
- Monni, Laura
Kraus, Larissa
Dipper‐Wawra, Matthias
Soares‐da‐Silva, Patricio
Maier, Nikolaus
Schmitz, Dietmar
Holtkamp, Martin
Fidzinski, Pawel - Abstract:
- Abstract : Background and Purpose: The KCNQ2 gene encodes for the Kv 7.2 subunit of non‐inactivating potassium channels. KCNQ2 ‐related diseases range from autosomal dominant neonatal self‐limited epilepsy, often caused by KCNQ2 haploinsufficiency, to severe encephalopathies caused by KCNQ2 missense variants. In vivo and in vitro effects of the sodium channel blocker eslicarbazepine acetate (ESL) and eslicarbazepine metabolite (S‐Lic) in a mouse model of self‐limited neonatal epilepsy as a first attempt to assess the utility of ESL in the KCNQ2 disease spectrum was investigated. Experimental Approach: Effects of S‐Lic on in vitro physiological and pathological hippocampal neuronal activity in slices from mice carrying a heterozygous deletion of Kcnq2 ( Kcnq2 +/− ) and Kcnq2 +/+ mice were investigated. ESL in vivo efficacy was investigated in the 6‐Hz psychomotor seizure model in both Kcnq2 +/− and Kcnq2 +/+ mice. Key Results: S‐Lic increased the amplitude and decreased the incidence of physiological sharp wave–ripples in a concentration‐dependent manner and slightly decreased gamma oscillations frequency. 4‐Aminopyridine‐evoked seizure‐like events were blocked at high S‐Lic concentrations and substantially reduced in incidence at lower concentrations. These results were not different in Kcnq2 +/+ and Kcnq2 +/− mice, although the EC50 estimation implicated higher efficacy in Kcnq2 +/− animals. In vivo, Kcnq2 +/− mice had a lower seizure threshold than Kcnq2 +/+ mice. In bothAbstract : Background and Purpose: The KCNQ2 gene encodes for the Kv 7.2 subunit of non‐inactivating potassium channels. KCNQ2 ‐related diseases range from autosomal dominant neonatal self‐limited epilepsy, often caused by KCNQ2 haploinsufficiency, to severe encephalopathies caused by KCNQ2 missense variants. In vivo and in vitro effects of the sodium channel blocker eslicarbazepine acetate (ESL) and eslicarbazepine metabolite (S‐Lic) in a mouse model of self‐limited neonatal epilepsy as a first attempt to assess the utility of ESL in the KCNQ2 disease spectrum was investigated. Experimental Approach: Effects of S‐Lic on in vitro physiological and pathological hippocampal neuronal activity in slices from mice carrying a heterozygous deletion of Kcnq2 ( Kcnq2 +/− ) and Kcnq2 +/+ mice were investigated. ESL in vivo efficacy was investigated in the 6‐Hz psychomotor seizure model in both Kcnq2 +/− and Kcnq2 +/+ mice. Key Results: S‐Lic increased the amplitude and decreased the incidence of physiological sharp wave–ripples in a concentration‐dependent manner and slightly decreased gamma oscillations frequency. 4‐Aminopyridine‐evoked seizure‐like events were blocked at high S‐Lic concentrations and substantially reduced in incidence at lower concentrations. These results were not different in Kcnq2 +/+ and Kcnq2 +/− mice, although the EC50 estimation implicated higher efficacy in Kcnq2 +/− animals. In vivo, Kcnq2 +/− mice had a lower seizure threshold than Kcnq2 +/+ mice. In both genotypes, ESL dose‐dependently displayed protection against seizures. Conclusions and Implications: S‐Lic slightly modulates hippocampal oscillations and blocks epileptic activity in vitro and in vivo . Our results suggest that the increased excitability in Kcnq2 +/− mice is effectively targeted by S‐Lic high concentrations, presumably by blocking diverse sodium channel subtypes. … (more)
- Is Part Of:
- British journal of pharmacology. Volume 179:Number 1(2022)
- Journal:
- British journal of pharmacology
- Issue:
- Volume 179:Number 1(2022)
- Issue Display:
- Volume 179, Issue 1 (2022)
- Year:
- 2022
- Volume:
- 179
- Issue:
- 1
- Issue Sort Value:
- 2022-0179-0001-0000
- Page Start:
- 84
- Page End:
- 102
- Publication Date:
- 2021-11-09
- Subjects:
- acute seizures models -- encephalopathy -- eslicarbazepine acetate -- hippocampal oscillations -- mouse -- seizure‐like event
Pharmacology -- Periodicals
Chemotherapy -- Periodicals
Drug Therapy -- Periodicals
Pharmacology -- Periodicals
615.1 - Journal URLs:
- http://bibpurl.oclc.org/web/21844 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1476-5381/issues ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=282&action=archive ↗
http://onlinelibrary.wiley.com/ ↗
http://www.nature.com/bjp/index.html ↗ - DOI:
- 10.1111/bph.15689 ↗
- Languages:
- English
- ISSNs:
- 0007-1188
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2314.700000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 26744.xml